INAB
In8bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.08M
P/E Ratio
—
EPS
$-4.53
Beta
0.04
52W High
$5.82
52W Low
$1.17
50-Day MA
$1.78
200-Day MA
$2.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About In8bio Inc
IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-18.09M |
| Operating Margin | 0.00% |
| Return on Equity | -92.50% |
| Return on Assets | -46.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.82 |
| Price-to-Book | 0.51 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.85M |
| Float | $7.03M |
| % Insiders | 20.68% |
| % Institutions | 32.78% |
Analyst Ratings
Consensus ($6.25 target)
1
Strong Buy3
BuyData last updated: 4/8/2026